Rubius Therapeutics — Investor Presentation (January 2020)
33 slides from Rubius Therapeutics's investor presentation, Jan 13, 2020
Slide 1: Realizing the Power of RED: A New Era in Cellular Medicine
Pablo J. Cagnoni , M.D., Chief Executive Officer JANUARY 2020 REALIZING THE POWER OF RED ™ : A NEW ERA IN CELLULAR MEDICINE
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation may contain forward - looking statements . Forward - looking statements are neither historical facts nor assurances of future performance . Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business
Slide 3: 2019 Achievements: Setting the Stage for Success
2019 Achievements: Setting the Stage for Success 3 STRENGTHENED ORGANIZATION & DELIVERED MILESTONES Accelerated Rubius manufacturing site buildout and GMP operations Manufactured clinical - grade RTX - 134 at contract manufacturing organization Filed IND and received clearance for first - ever RCT –
Slide 4: Advances and Limitations of Current Cell Therapies
Advances and Limitations of Current Cell Therapies 4 Significant opportunities in oncology and beyond for more potent and less toxic cellular medicines • Limited to certain hematologic cancers • Severe side effects • Unpredictable pharmacokinetics and biodistribution • Costly manufacturing • No appr
Slide 5: Harnessing the Unique Properties of Red Blood Cells
Harnessing the Unique Properties of Red Blood Cells 5 • Have a circulation time of ~120 days • Lack a nucleus • Have a predictable biodistribution in the vasculature • > 100 - year history of administering blood to patients WHY RED BLOOD CELLS? O NEGATIVE RBCs CAN BE GIVEN TO ~ 95% OF PEOPLE
Slide 6: Red Cell Therapeutics
Red Cell Therapeutics™ 6 POTENTIALLY TRANSFORMATIVE CELLULAR THERAPIES OFF - THE - SHELF BROAD THERAPEUTIC APPLICATIONS PREDICTABLE BIODISTRIBUTION DEFINED LIFE IN CIRCULATION AND CONVENIENT DOSING ADVANTAGEOUS TOLERABILITY SCALABLE MANUFACTURING RARE DISEASE CANCER AUTOIMMUNE
Slide 7: The Promise of Red Cell Therapeutics: Highly Potent, Allogeneic and Off-the-Shelf
The Promise of Red Cell Therapeutics™: Highly Potent, Allogeneic and Off - the - Shelf 7 Red Cell Therapeutic (RCT) dose expected to be <1% of normal red cell volume GENETIC E NGINEERING SINGLE HEALTHY O - DONOR EXPANSION & DIFFERENTIATION RED CELL THERAPEUTIC ENUCLEATION & MATURATION RED PLATFORM ®
Slide 8: RED PLATFORM Enables Multiple Modalities
RED PLATFORM ® Enables Multiple Modalities 8 RARE ENZYME DEFICIENCIES ENZYME REPLACEMENT CELLULAR SHIELDING ENZYMES WITHIN THE RCT CANCER IMMUNE STIMULATION POTENT CELL - CELL INTERACTION AUTOIMMUNE DISEASES IMMUNE MODULATION ANTIGEN - SPECIFIC IMMUNOMODULATORS T CELL NK CELL ANTIGEN - SPECIFIC IMMU
Slide 9: Building a Broad and Diverse Pipeline
Building a Broad and Diverse Pipeline 9 PRODUCT CATEGORY PATIENT POPULATION PROGRAM PRECLINICAL IND ENABLING PHASE 1 RARE DISEASES 50,000+ RTX - 134 FPI* & Initial Clinical Data Expected 100,000+ RTX - Uricase 2,000 - 4,000 RTX - CBS 20,000+ RTX - OxOx CANCER 100,000+ RTX - 240 IND on File with FDA
Slide 10: Manufacturing
(RubiusTherapeutics MANUFACTURING
Slide 11: Manufacturing Update
Manufacturing Update 11 • Expected to provide supply for RTX - 240 and RTX - 321 trials • CMO producing RTX - 134 for current Phase 1b clinical trial • Rubius manufacturing site operational • Delivered nine months ahead of schedule • Potential to expand manufacturing capabilities based on future nee
Slide 12: Phenylketonuria
( ubiusTherapeutics PHENYLKETONURIA
Slide 13: RTX-134 for the Potential Treatment of Phenylketonuria
• RTX - 134 shields immunogenic PAL enzyme from the immune system • PAL metabolizes and converts Phe to TCA • Target indication: patients with serum Phe levels ≥ 600 μ mol/L • Infrequent, low volume IV administration • Seek Orphan Drug Designation • Deficiency of the enzyme needed to break down diet
Slide 14: RTX-134: Simple Three-Step Mechanism of Action
Trans - Cinnamic Acid (TCA) Phenylalanine ( Phe ) RTX - 134: Simple Three - Step Mechanism of Action 14 Phe Naturally Enters RTX - 134 as it Circulates 1 TCA Exits RTX - 134 and is Processed by the Body 3 PAL Enzyme Breaks Down Phe into TCA inside RTX - 134 2
Slide 15: RTX-134 Phase 1b Clinical Trial Design
SINGLE ASCENDING DOSE OF RTX - 134 N=UP TO 12 PATIENTS RTX - 134 Phase 1b Clinical Trial Design 15 Cohort 1 Cohort 2 Cohort 3 Cohort 4 n=2 n=2 n=2 n=2 Optional Cohort 5 Optional Cohort 6 Study design provides flexibility to enroll additional patients to certain cohorts or add additional cohorts PRIM
Slide 16: Initial Clinical Results
Initial Clinical Results 16 INITIAL CLINICAL DATA EXPECTED TO INCLUDE: PHASE 1B SINGLE DOSE ADMINISTRATION CLINICAL STUDY • Preliminary safety • Longevity of cells in circulation • Production of TCA as biomarker of MOA
Slide 17: Cancer
ubiusTherapeutics CANCER
Slide 18: Challenges of Agonist Monoclonal Antibodies and Recombinant Cytokines
Challenges of Agonist Monoclonal Antibodies and Recombinant Cytokines 18 1 Barthowiak , et. al., Clinical Cancer Research ; 24(5) March 1, 2018 AGONIST ANTIBODIES AND RECOMBINANT CYTOKINES • Artificially engineered • Limited combinability due to toxicity • Systemic administration floods the liver an
Slide 19: Rubius Therapeutics' Differentiated Oncology Approaches
Rubius Therapeutics’ Differentiated Oncology Approaches BROAD IMMUNE SYSTEM STIMULATION 19 • Stimulate adaptive and innate immunity through immune cell agonists – Presentation of synergistic co - stimulatory ligands and cytokines – Vascular compartmentalization may reduce toxicities – Potential broa
Slide 20: A Potentially Transformative Approach to Oncology: RTX-240
A Potentially Transformative Approach to Oncology: IND Under Review with FDA & FPI Expected in 2H’20 20 BROAD IMMUNE SYSTEM STIMULATION POTENTIAL BENEFITS: • Improved anti - tumor activity • Overcome resistance to immunotherapy • Reduced toxicity given vascular compartmentalization 4 - 1BBL NK CELL
Slide 21: Realizing the Promise of the 4-1BB Pathway: RTX-240
U t o m i l + X - l i n k i n g A b R T X - 2 1 2 R T X - C T R L 0 25 50 75 100 125 N F k B p a t h w a y a c t i v a t i o n ( f o l d i n c r e a s e o v e r n o t r e a t m e n t ) Realizing the Promise of the 4 - 1BB Pathway: RTX - 240 Stimulated Potent Activation of Immune System 21 NF k B ACT
Slide 22: mRCT-240 Inhibits Tumor Growth as Monotherapy or with Anti-PD-1 mAb
mRCT - 240 Inhibits Tumor Growth as Monotherapy or in Combination with Anti - PD - 1 mAb 22 m R C T - C T R L I V P D 1 m A b I V m R C T - 2 4 0 + P D 1 m A b I V 0 50 100 150 200 250 M e t a s t a s e s p e r L u n g p = 0.0025 mRCT - 240 + anti - PD - 1 mAb reduced tumor burden vs. anti - PD - 1
Slide 23: Lack of Liver Toxicity in Preclinical Models
Lack of Liver Toxicity in Preclinical Models Suggests Better Therapeutic Window than 4 - 1BB mAbs 23 m R C T - C T R L m R C T - 2 1 2 1 E 9 P D 1 m A b 1 5 0 u g m R C T - 2 1 2 1 E 9 + P D 1 m A b 1 5 0 u g 4 - 1 B B m A b 2 0 0 u g 4 - 1 B B m A b m A b 5 0 u g 0 1 10 7 2 10 7 3 10 7 4 10 7 # F 4
Slide 24: RCTs as Artificial Antigen Presenting Cells (aAPC)
ANTIGEN - SPECIFIC IMMUNE STIMULATION RCTs as Artificial Antigen Presenting Cells ( aAPC ) 24 Selective tumor killing by expanding tumor - specific T cells POTENTIAL BENEFITS Designed to replicate immune system function to activate and expand antigen - specific T cells for a potent anti - tumor effe
Slide 25: mRBC-aAPC (gp100) Promotes Antigen-Specific T-Cell Expansion
mRBC - aAPC (gp100) Promotes Antigen - Specific T - Cell Expansion 25 CIRCULATION SPLEEN m R B C - C T R L 1 1 0 9 2 . 5 1 0 8 6 1 0 7 0 1 10 5 2 10 5 3 10 5 4 10 5 Pmel Number C D 9 0 . 1 + C D 8 + n u m b e r ** mRBC-gp100-4-1BBL-IL-12 Pmel Number Pmel Number Antigen - specific T cell expansion oc
Slide 26: mRBC-aAPC (gp100) Nearly Eliminates Lung Metastases in Melanoma Model
mRBC - aAPC (gp100) Nearly Eliminates Lung Metastases in Melanoma Model 26 Lung Metastases Count mRBC - CTRL m R B C - C T R L 1 × 1 0 9 2 . 5 × 1 0 8 6 × 1 0 7 0 50 100 150 200 250 Lung Metastasis Count L u n g M e t a s t a s i s C o u n t ** ** ** mRBC-gp100-4-1BBL-IL-12 mRBC - aAPC (gp100) Zhang
Slide 27: Artificial Antigen Presenting Cells to Target HPV 16+ Cancers
Artificial Antigen Presenting Cells to Target HPV 16+ Cancers 27 ANTIGEN - SPECIFIC IMMUNE STIMULATION Replicating immune system function to activate and expand antigen - specific T cells for a potent anti - tumor effect RTX - 321 | HPV 16+ Tumors T CELL Signal 2: 4 - 1BBL Antigen - Specific TCR MHC
Slide 28: RTX-321 (HPV+) Demonstrates In Vitro Activity
RTX - 321 (HPV+) Demonstrates In Vitro Activity 28 0 1×10 6 2×10 6 3×10 6 4×10 6 0 2 4 6 8 10 RTX Cell Number H P V T C R A c t i v a t i o n ( F o l d c h a n g e i n L u m i n e s e n c e ) RTX-null RTX-321 (HPV+) RTX-aAPC (CMV) • HPV - driven cancers are a global health burden and a foremost caus
Slide 29: Intellectual Property
ubiusTherapeutics INTELLECTUAL PROPERTY
Slide 30: Potential to Realize Broad Depth of Value of Red Cell Therapeutics
Potential to Realize Broad Depth of Value of Red Cell Therapeutics 30 BROAD AND DEEP INTELLECTUAL PROPERTY COVERING: RAPIDLY EXPANDING PATENT PORTFOLIO Pioneering processes for engineering and culturing RCT product candidates Issued U.S. patents cover RTX - 134, RTX - 240, RTX - 224 and RTX - 321 Co
Slide 31: ubiusTherapeutics
ubiusTherapeutics
Slide 32: Anticipated 2020 Milestones: A Year of Execution
Anticipated 2020 Milestones: A Year of Execution 32 AN INTEGRATED DEVELOPMENT COMPANY RTX - 321 IND filing by year - end STRONG FINANCIAL POSITION • $324.7 million in cash, cash equivalents and investments as of September 30, 2019 GMP material for RTX - 240 and RTX - 321 trials from Rubius site RTX
Slide 33: Realizing the Power of RED: A New Era in Cellular Medicine
REALIZING THE POWER OF RED ™ : A NEW ERA IN CELLULAR MEDICINE
Rubius Therapeutics — Investor Presentation (January 2020) on 6ix